Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats

Hypertension

Volumn 48, Issue 5, 2006, Pages 972-978

  Masuyama, Hiroyuki ^a   Tsuruda, Toshihiro ^a,b   Kato, Johji ^a   Imamura, Takuroh ^a   Asada, Yujiro ^a   Stasch, Johannes Peter ^c   Kitamura, Kazuo ^a   Eto, Tanenao ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b MINAMI KYUSHU UNIVERSITY   (Japan)

^c BAYER PHARMA AG   (Germany)

Author keywords

cGMP; Extracellular matrix; Fibrosis; Hypertension; Soluble guanylate cyclase

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ANGIOTENSIN II; COLLAGEN; COLLAGEN TYPE 1; CYCLIC GMP; GUANYLATE CYCLASE ACTIVATOR; THYMIDINE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR REMODELING; CELL COUNT; CELL CULTURE; CONTROLLED STUDY; CORONARY ARTERY; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVATION; FIBROBLAST; GENE EXPRESSION; HEART DISEASE; HEART MUSCLE FIBROSIS; HEART WEIGHT; HYPERTENSION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CARDIOVASCULAR SYSTEM; CELLS, CULTURED; GUANYLATE CYCLASE; HYPERTENSION; MALE; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR; SOLUBILITY;

EID: 33750242986     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000241087.12492.47     Document Type: Article

References (27)

1. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000;102:470-479.
2. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res. 1999;41:532-543.
3. Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart failure. Cardiovasc Res. 1999;45:813-825.
4. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
6. Weber KT. Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. J Hypertens. 2004;22:47-50.
7. Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Devereux RB, Ibsen H. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Am Heart J. 2002;144:530-537.
8. Rosenkranz S. TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-432.
9. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblast. J Clin Invest. 1998;101:812-818.
10. Mori T, Chen YF, Feng JA, Hayashi T, Oparil S, Perry GJ. Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse. Cardiovasc Res. 2004;61:771-779.
11. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 1995;25:227-234.
12. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC Jr. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002;91:1127-1134.
13. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci. 2000;97:4239-4244.
14. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schröder H, Stahl E, Steinke W, Wunder F. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002;136:773-783.
15. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Denbowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiß U, Schröder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature (Lond). 2001;410:212-215.
16. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC Jr. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY41-2272 in experimental congestive heart failure. Circulation. 2003;107:686-689.
17. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation. 2004;110:2253-2259.
18. Tsuruda T, Kato J, Hatakeyama K, Masuyama H, Cao YN, Imamura T, Kitamura K, Asada Y, Eto T. Antifibrotic effect of adrenomedullin on coronary adventitia in angiotensin II-induced hypertensive rats. Cardiovasc Res. 2005;65:921-929.
19. Naito Y, Tsujino T, Fujioka Y, Ohyanagi M, Iwasaki T. Augmented diurnal variations of the cardiac renin-angiotensin system in hypertensive rats. Hypertension. 2002;40:827-833.
20. Tsuruda T, Kato J, Kitamura K, Kawamoto M, Kuwasako K, Imamura T, Koiwaya Y, Tsuji T, Kangawa K, Eto T. An autocrine or a paracrine role of adrenomedullin in modulating cardiac fibroblast growth. Cardiovasc Res. 1999;43:958-967.
21. Hirano S, Imamura T, Matsuo T, Ishiyama Y, Kato J, Kitamura K, Koiwaya Y, Eto T. Differential responses of circulating and tissue adrenomedullin and gene expression to volume overload. J Card Fail. 2000;6:120-129.
22. Weber KT. Cardioreparation in hypertensive heart disease. Hypertension. 2001;38:588-591.
23. Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H, Takemiya K, Koga M, Yamamoto T, Imaizumi T. Pressure-independent effects of Angiotensin II on hypertensive myocardial fibrosis. Hypertension. 2004;43:499-503.
24. Andreopoulos S, Papapetropoulos A. Molecular aspects of soluble guanylyl cyclase regulation. Gen Pharmacol. 2000;34:147-157.
25. Straub A, Benet-Buckholz J, Fröde R, Kern A, Kohlsdorfer C, Schmitt P, Schwarz T, Siefert HM, Stasch JP. Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase. Bioorg Med Chem. 2002;10:1711-1717.
26. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-β1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997;29:1947-1958.
27. Rosenkranz AC, Woods RL, Dusting GJ, Ritchie RH. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: Importance of cyclic GMP. Cardiovasc Res. 2003;57:515-522.